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TLQP-21, a VGF-encoded peptide is emerging as a
novel target for obesity-associated disorders. TLQP-
21 is found in the sympathetic nerve terminals in the
adipose tissue and targets the G-protein-coupled
receptor complement-3a receptor1 (C3aR1). The
mechanisms of TLQP-21-induced receptor activation
remain unexplored. Here, we report that TLQP-21 is
intrinsically disordered and undergoes a disorder-
to-order transition, adopting an a-helical conforma-
tion upon targeting cells expressing the C3aR1. We
determined that thehot spots for TLQP-21are located
at theC terminus,withmutations in the last four amino
acids progressively reducing the bioactivity and,
a single site mutation (R21A) or C-terminal amidation
abolishing its function completely. Additionally, the
human TLQP-21 sequence carrying a S20A sub-
stitution activates the human C3aR1 receptor with
lower potency compared to the rodent sequence.
These studies reveal the mechanism of action
of TLQP-21 and provide molecular templates for
designing agonists and antagonists to modulate
C3aR1 functions.
INTRODUCTION
The Vgf gene is a member of the extended granin family of pep-
tide-precursor proteins that encodes a 615 amino acid propep-
tide (617 in rodents) (Bartolomucci et al., 2011). This propeptide
is processed to yield several bioactive fragments, with at least
eight possessing nonredundant biological functions (Bartolo-
mucci et al., 2011; Hahm et al., 1999). Due to their involvement
in the pathophysiology of human diseases such as psychiatric,
neurological, andmetabolic disorders, as well as several tumors,1744 Structure 22, 1744–1753, December 2, 2014 ª2014 Elsevier LtdVGF peptide fragments are also being investigated as possible
disease biomarkers (Bartolomucci et al., 2011). The best-studied
fragment is the C-terminal internal peptide designated TLQP-21,
the sequence and function of which we have identified and
extensively characterized (Bartolomucci et al., 2006). TLQP-21
is amultifunctional peptide that regulates energy balance (Barto-
lomucci et al., 2006; Jethwa et al., 2007; Possenti et al., 2012),
glucose metabolism (Stephens et al., 2012), gastric function
(Severini et al., 2009), nociception (Rizzi et al., 2008; Chen
et al., 2013; Fairbanks et al., 2014), blood pressure regulation
(Fargali et al., 2014), reproduction (Aguilar et al., 2013), and
stress (Razzoli et al., 2012). Importantly, it was found that a cen-
tral infusion of TLQP-21 increases energy expenditure and pre-
vents obesity in rodents (Bartolomucci et al., 2006; Jethwa
et al., 2007). Additionally, chronic peripheral infusions of
TLQP-21 in obese rodents led to decreased adipocyte diameter
(Possenti et al., 2012), improved hypertension (Fargali et al.,
2014), and diabetes (Stephens et al., 2012), making it an impor-
tant target to counteract obesity-associated disorders. How-
ever, the molecular mechanisms of TLQP-21 function are still
largely unknown. The recent discovery that TLQP-21 directly tar-
gets the complement 3a receptor 1 (C3aR1) has reinvigorated
both physiological and pharmacological interest in this peptide
as a potential drug target (Hannedouche et al., 2013). C3aR1 is
a member of the G-protein-coupled receptor (GPCR) superfam-
ily, characterized by seven transmembrane domains and a large
second extracellular loop (Klos et al., 2013; Roglic et al., 1996).
Although its role in the innate immune response is well estab-
lished, C3aR1 is now emerging with a much broader pattern of
expressions in different tissues and functions involving cell
metabolism (e.g., Mamane et al., 2009; Lo et al., 2014). In
obesity, a significant increase of adipose-tissue specific
C3aR1 expression has been found (Mamane et al., 2009), with
a concomitant increase of TLQP-21 binding affinity (Possenti
et al., 2012). Additionally, knockout studies targeting C3,
C3aR1, and VGF suggest direct involvement of the C3aR1
receptor in both adiposity and energy balance (Mamane et al.,All rights reserved
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Figure 1. TLQP-21 Binding in 3T3L1 and
CHO Cells and Activity at the C3aR1
(A) Photoactivated crosslinking of a modified
TLQP-21 peptide (CL) in CHO and 3T3L1 cells.
CHO membranes were treated with PBS or CL
(100 mM). A band of 56 kDa was observed with
anti-TLQP21 in membrane fractions P1 and P2
from CL-treated but not PBS-treated membranes.
Labeling remained in the protein pellet when P2
membranes were TCA-precipitated (P2 ppt). P2
membranes from 3T3L1 cells were treated with
PBS or increasing concentrations of CL.
(B) Crosslinking of a modified TLQP-21 peptide
(CL) to membranes prepared from 3T3L1 cells is
reduced in the presence of the C3aR1 antagonist
SB290157. Lanes 2 and 3 show that crosslinking is
not affected by DMSO used to dissolve SB290157.
(C) The b-arrestin recruitment assay showed that
TLQP-21 is an agonist for the human C3aR1,
similar to the human C3a peptide. The mouse
TLQP-21 has higher potency than the human
TLQP-21.
Structure
Structural and Functional Analysis of TLQP-21 Peptide2009; Hahm et al., 1999, 2002; Roy et al., 2008; Fargali et al.,
2012; Watson et al., 2005). Here, we used solid-state nuclear
magnetic resonance (NMR) spectroscopy in combination with
photoaffinity labeling, biological assays, as well as alanine-
scanning mutagenesis to elucidate the structural determinants
of TLQP-21 binding to C3aR1. We studied the binding of
TLQP-21 to cells expressing the receptor as well as receptor
knockout cells. We found that the TLQP-21 peptide is intrinsi-
cally disordered but adopts an ordered helical conformation
upon interacting with cells expressing the C3aR1 receptor.
Furthermore, we determined that the C-terminal domain of the
peptide comprises the hot spots for its biological function,
with the R21A mutation able to abrogate TLQP-21 activity
completely. Finally, we found that the human sequence of
TLQP-21 carrying a S20A substitution activates human C3aR1
receptor with lower potency than the rodent sequence. Overall,
these studies reveal a folding-upon-binding mechanism for the
activation of the C3aR1 receptor by the TLQP-21 peptide, and
identify the hot spots to tune its biological function.
RESULTS
TLQP-21 Targets the C3aR1 Receptor
To establish the selective binding of the TLQP-21 to the C3aR1
receptor, we carried out photoaffinity labeling experiments. First,
we synthesized a biotin-conjugated TLQP-21 peptide, substitut-
ing F13 with a benzophenone derivative; we then incubated the
peptide with both 3T3L1 and CHO cells that express the C3aR1
(Figure S1 available online; Possenti et al., 2012; Choy et al.,Structure 22, 1744–1753, December 2, 20141992; Cassina et al., 2013). Upon UV irra-
diation of the reaction mixture, the modi-
fied peptide consistently crosslinked
with a protein running at approximately
55 kDa on the SDS-PAGE, corresponding
to the nominal molecular weight of the
C3aR1 receptor (Klos et al., 2013; Roglic
et al., 1996) (Figure 1A). To test the bindingspecificity of the TLQP-21 for the C3aR1 receptor, we carried
out the same reaction in the presence of SB290157, a well-
documented C3aR1 antagonist (Ames et al., 2001). In the pres-
ence of the antagonist, we observed a substantial reduction
in crosslinking efficiency (Figure 1B), indicating that SB290157
competes with TLQP-21 binding to the C3aR1 receptor.
To provide additional evidence that TLQP-21 targets the
C3aR1, we used a b-arrestin recruitment assay in HTLA cells
transfected with the human C3aR1 receptor (Lin et al., 2013).
We found that the half-maximal effective concentration (EC50)
for mouse TLQP-21 is approximately three times lower than that
of C3a, and the EC50 for the human TLQP-21 is approximately
22 times lower than that of C3a (Figure 1C; EC50, C3a = 3.0 mM;
mouse TLQP-21 = 10.3 mM; human TLQP-21 = 68.8 mM), indi-
cating that both human and mouse TLQP-21 species are active
toward human C3aR1, although with different potency.
TLQP-21 Undergoes a Disorder-to-Order Transition
upon Binding C3aR1
Secondary structure predictions showed that the TLQP-21
sequence has a low propensity to form a well-order a helix
(Garcia et al., 2005) (Figure S2). Accordingly, solution NMR
experiments in aqueous solutions showed that the peptide is
essentially unstructured, with a chemical shift index typical of
random coil conformations (Figure S2). Addition of the helix
promoting solvent trifluoroethanol or dodecyl phosphocholine
micelles left the resonances of the peptide essentially unper-
turbed, excluding its propensity to adopt an ordered confor-
mation in membrane-mimicking environments (Figure S2). Weª2014 Elsevier Ltd All rights reserved 1745
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Figure 2. Structural Analysis of TLQP-21 in the Presence of Target 3T3L1 Cells
(A–F) Overlay spectra of refocused INEPT spectrum of TLQP-21 13C and 15N labeled at P4-R6-A9 (A and B), P4-A6-R9-R11-P19-A20 (C and D), or A16-L17-P18 (E and
F) with resonance assignments indicated. Experiments were performed in buffer (A, C, and E) or in the presence of 3T3L1 cells after 24 hr incubation at 37C
(B, D, and F).
(G and H) Chemical shift index of TLQP-21 in buffer (red) or in the presence of 3T3L1 cells (blue) (Schwarzinger et al., 2000).
Structure
Structural and Functional Analysis of TLQP-21 Peptidethen tested thepeptide’s interactionswith lipidmembranes using
magic angle spinning (MAS) solid-state NMR spectroscopy. To
depict the peptide, we synthesized three different TLQP-21
analogs with 15N, 13C labels interspersed throughout its primary
sequence: TLQP-21-ALP, labeled at A16, L17, P18; TLQP-21-
PAR, labeled at P4, A6, R9; and TLQP-21-PARRPA, labeled P4,
A6, R9, R11, P19, A20. (Figure S3). We performed two different
experiments: the refocused insensitive nuclei enhancedbypolar-
ization transfer (rINEPT) experiment, which is sensitive to more
dynamic regions of proteins (Fyfe et al., 1995), and cross-polari-
zation experiments (Engelke and Steuernagel 2007), which
detect more rigid domains (Figure S3). The peptide was recon-
stituted with large unilamellar vesicles of DOPC:DOPE. Under
these conditions, we did not observe any peptide resonances
in the cross-polarization spectra, excluding a strong binding of
the peptide to themembrane vesicles, and at the same time sup-
porting the dynamic nature of the peptide. In contrast, the rINEPT
experiment detected essentially all of the labeled sites, display-
ing a well-resolved spectrum of TLQP-21 with chemical shift
values corresponding to the tabulated random coil values
(http://www.bmrb.wisc.edu) (Figures 2A, 2C, and 2E; Fig-
ure S2D). Taken with the solution NMR experiments, the solid-
state NMR spectra showed that the peptide is intrinsically
disordered in solution and does not have a strong tendency to
associate with lipid bilayers. To test TLQP-21 binding under the
native conditions rather than in a reconstituted system, we
probed the peptide-receptor interactions by incubating the pep-
tidewith 3T3L1 cells that expressC3aR1 (FigureS1). Under these
conditions, TLQP-21 underwent a disorder-to-order transition1746 Structure 22, 1744–1753, December 2, 2014 ª2014 Elsevier Ltd(Figures 2B, 2D, and 2F). Specifically, the chemical shifts of the
Ca-Ha resonances changed significantly (Figures 2G and 2H),
consistent with a structural transition from random coil to
a-helical conformation (Figure 3). The experiment was repeated
for three labeled TLQP-21 analogs spanning the core sequence,
and in all cases, we observed the same chemical shift transitions
from random coil to helix (Figure 2).
To confirm the specificity of the binding under NMR condi-
tions, we analyzed TLQP-21 binding in the presence of N2-
[(2,2-diphenylethoxy)acetyl-L-arginine (or SB290157), a potent
inhibitor of C3aR1 that does not antagonize either C5aR or other
GPCRs (Ames et al., 2001). Because the concentration of the re-
ceptor is unknown, we used 5 mM of the inhibitor. In the spec-
trum of TLQP-PAR (Figure 4C), we detected two conformations
of the peptide: one with chemical shifts corresponding to the
unfolded peptide, and a weaker set matching the helical struc-
ture. These data indicate that there is only a partial saturation
of the receptor on the adipocytes with the SB290157 inhibitor.
To circumvent this issue, we used splenocytes derived from
either wild-type mouse expressing C3aR1 receptor (Kwan
et al., 2013), or from a C3aR1 knockout mouse. Again, for the
wild-type cells we observe the backbone chemical shifts match-
ing those of the folded helical conformation (Figure 4E).
Conversely, TLQP-21 incubated with the C3aR1 knockout sple-
nocytes exhibits chemical shifts such as those of the unfolded
structure (Figure 4F). Finally, although the N38 cell line has
been proposed as a negative control for TLQP-21 activity (Cas-
sina et al., 2013), we detected significant expression of the
C3aR1 receptor using QPCR (Figure S1). As a result, we haveAll rights reserved
Figure 3. A Structural Model of TLQP-21 upon Receptor Binding
The backbone conformation was obtained with XPLOR-NIH software
(Schwieters et al., 2003) constraining the dihedral angles of the residues
showing helical chemical shifts. The conformation of the side chains is arbi-
trary. Electrostatic surface calculated with APBS (Baker et al., 2001) illustrates
the positively charged N-terminal domain of TLQP-21 and primarily neutral
C-terminal domain.
Structure
Structural and Functional Analysis of TLQP-21 Peptideobserved binding of the TLQP-21 peptide to the receptor with
concomitant transitions from disordered to helical conformation
(Figure S4).
Determination of the Hot Spots for TLQP-21 Biological
Function
After establishing the structural determinant of TLQP-21 binding
to C3aR1, we sought to identify the hot spots for the peptide
activity. The primary amino acid sequence of murine TLQP-21
(TLQPPASSRRRHFHHALPPAR) corresponds to amino acids
556–576 of the VGF propeptide (Bartolomucci et al., 2006,
2011). One of the best-characterized bioassays for TLQP-21
activity is the contraction of stomach fundus strips (Severini
et al., 2009). At a dose of 3 mM, TLQP-21 induces up to 69%
of the corresponding contraction promoted by acetylcholine.
To elucidate the hot spots responsible for optimal biological
activity, we synthesized and tested the biological response of
two truncated analogs of the TLQP-21 peptide: one without
the C-terminal sequence (TLQP-11), and the second without
the N terminus (HFHH-10). We found that TLQP-11 is essentiallyStructure 22, 1744–17inactive, with zero response at concentrations up to 10 mM
(Table 1), whereas HFHH-10 induced a modest biological activ-
ity, with3% response at a concentration of 3 mM, 62% at 6 mM,
and 75% at 10 mM. These experiments suggest that the hot
spots for biological activity are situated at the C terminus, and
demonstrate that the entire peptide sequence is required for its
optimal activity. We next performed Ala-scanning mutagenesis
(Morrison and Weiss 2001) on the C-terminal portion of TLQP-
21. We found that mutations of endogenous amino acids with
Ala had no significant effects, with the exception of the four
C-terminal amino acids. Specifically, the P18A mutant showed
partial biological function with 65% activity at 3 mM. The
P19A mutant showed only residual activity with 19% at 3 mM
(and 35% at 6 mM) (Table 1; Figure S5). Interestingly, the human
TLQP-21, in which Ser is in position 20 (Ala for the rodent
sequence), showed limited biological activity toward the rodent
receptor with 20% at 3 mM compared to the mouse sequence
(Table 1), a finding that is in line with the b-arrestin activity assays
reported in Figure 1C. Importantly, the R21Amutant resulted in a
complete loss of activity (Table 1; Figure S5), even after
increasing the dose up to 10 mM. The inactive R21A mutant
does not block the activity of a subsequent infusion of
TLQP-21, suggesting that it does not behave as a C3aR1 antag-
onist (Table 1; Figure S5). Note that under our conditions the bio-
logical activity elicited by TLQP-21 is similar to that of the C3aR1
agonist C3a70–77 (Hugli and Erickson 1977), with 3 mM TLQP-21
and C3a70–77 causing approximately 69% and 55% contraction
of fundus strips, respectively, relative to acetylcholine (Fig-
ure S5). Finally, we investigated the effects of capping the
TLQP-21 C terminus via amidation. Although this posttransla-
tional modification is not observed for the TLQP-21 peptide
in vivo (Bartolomucci et al., 2006), it represents a prerequisite
for the activity of several other hormonal peptides such as corti-
cotropin-releasing hormone (Vale et al., 1981), and it increases
the stability of several synthetic peptides (Adessi and Soto
2002). Upon C-terminal amidation, the TLQP-21 peptide is
completely inactivated (Table 1), suggesting that the free
carboxylic group is necessary for activity.
Arginine 21 Is Essential for TLQP-21 Lipolysis in 3T3L1
Adipocytes
The above results support a central role of the C-terminal Arg for
TLQP-21 activity. To further understand the function of TLQP-21,
we assessed the prolipolytic effect of TLQP-21 in 3T3L1 adipo-
cytes and compared it to the R21A mutant. We found that
TLQP-21 does not increase lipolysis per se (Figure 5A; Figure S6),
but enhances isoproterenol-induced lipolysis in a dose-
dependent manner (Figure 5A). These results are in agreement
with our previous results obtained with mouse adipocytes (Pos-
senti et al., 2012). In contrast, we found that the R21A mutant
does not potentiate isoproterenol-induced lipolysis (Figure 5B)
or AMPK phosphorylation (Possenti et al., 2012) (Figure S6).
These results underscore the role of TLQP-21 as an enhancer
of bARs-induced lipolysis and highlight the critical role of Arg-
21 for activating C3aR1. Importantly, NMR spectra of the R21A
mutant (labeled with 13C and 15N at A16, L17, and P18) in the pres-
ence of 3T3L1 cells show a conformational transition similar to
that of the wild-type peptide (Figure 5C). Therefore, the loss-
of-function character of the inactive mutant is probably due to53, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1747
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Figure 4. Structural Analysis of TLQP-21 in
the Presence of C3aR1 Knockout Cells and
a C3aR1 Antagonist
(A–F) Refocused INEPT spectra of TLQP-21,
labeled with 13C and 15N at P4-A6-R9 with reso-
nance assignments indicated. Experiments were
performed in buffer (A and D), in the presence of
3T3L1 cells (B), in the presence of 3T3L1 cells
incubated with the C3aR1 antagonist SB290157
(C), in the presence of splenocytes derived from
wild-type (E), or in the presence of splenocytes
derived from a C3aR1 knockout mice (F).
Structure
Structural and Functional Analysis of TLQP-21 Peptidechanges in the electrostatic interactions at theC-terminal portion
of the peptide. The latter is supported by the chemical structure
of C3a (Hugli and Erickson 1977), by the analogous mutations at
R77 of C3a (Nettesheim et al., 1988), as well as the chemical
structure of the C3aR1 antagonist SB290157, which includes a
hydrophobic N-terminal diphenylethoxy group linked to the
acetyl-L-Arg moiety (Ames et al., 2001) that closely mimics the
C-terminal residues of the TLQP-21 peptide.
DISCUSSION
The role of the TLQP-21 neuropeptide in the pathophysiology of
gastrointestinal andmetabolic functions has been recognized by
several independent studies (Bartolomucci et al., 2011). Despite
this, the molecular mechanisms for eliciting TLQP-21 function
have remained elusive until a recent study identified the C3aR1
receptor as the target for TLQP-21 (Hannedouche et al., 2013).
Indeed, our photoaffinity-labeling andb-arrestin assays (Figure 1)
data support these previous studies, showing that TLQP-21
crosslinks with the C3aR1 receptor selectively. A second puta-
tive receptor for TLQP-21, the globular head of C1q has been
recently described (Chen et al., 2013). Published (Possenti
et al., 2012; Hannedouche et al., 2013; Cassina et al., 2013)
and current data do not support a second binding site in either
CHO or 3T3L1 cells (Figure 1), and there is no apparent struc-
tural/functional similarity between TLQP-21 and the predicted
C1q ligands (Gaboriaud et al., 2003).
Importantly, the NMR measurements demonstrated that the
peptide is intrinsically disordered in solution and does not
assume an ordered conformation upon the addition of helical-
inducing environments. However, when incubated with cells
expressing C3aR1, the TLQP-21 peptide undergoes a folding-
upon-binding transition, adopting a well-defined a-helical
conformation (Figure 3). This structural transition does not occur
in the presence of C3aR1-knockout cells and can be inhibited
upon treatment of 3T3L1 cells with a selective and competitive
antagonist of the C3aR1 receptor (Ames et al., 2001).1748 Structure 22, 1744–1753, December 2, 2014 ª2014 Elsevier Ltd All rights reservedTransition from a random coil to helix is
a common mechanism for activating
GPCRs of the secretin family (Shoichet
and Kobilka 2012; Hollenstein et al.,
2014; Parthier et al., 2009). For these re-
ceptors, the ligand peptides are disor-
dered in aqueous solutions, but adopted
a structured helical conformation uponbinding the extracellular domains of the receptors. The driving
force for their binding and folding is the formation of amphipathic
helices in which the hydrophobic residues embed into the bind-
ing site. At least six different examples have been reported in the
literature, e.g., corticotropin-releasing hormone, pituitary adeny-
late cyclase-activating peptide, glucagon, glucagon-like peptide
1, etc., where the high-resolution structures have been solved by
either NMR or X-ray crystallography (Pal et al., 2012). Whereas
the apparent mechanism of TLQP-21 helix folding is reminiscent
of these peptide hormones, the chemical nature of this VGF-
derived peptide is rather different, because the TLQP-21
sequence is flanked by two pairs of proline residues at both
termini. In the structural model derived from our chemical shift
measurements, hydrophobic and hydrophilic residues are not
segregated into two distinct faces of the helix; rather, the
charges are interspersed throughout the peptide sequence (Fig-
ure 3). This suggests a mechanism of recognition by the cognate
receptor that is different from that of other peptide hormones for
which a structural analysis has been conducted (Parthier et al.,
2009). Furthermore, the C terminus of peptides active at class
B GPCR acts as a docking site to initiate the helix formation,
and the N-terminal residues are responsible for the activation
of the receptors (Parthier et al., 2009; Karnik et al., 2003).
Conversely, peptides active at class A GPCR (including the
C3aR1) (Beck-Sickinger et al., 1994; Neelamkavil et al., 2005)
as well as other peptides of the granin family (Bartolomucci
et al., 2011) do not show a common binding mechanism. The
hot spots for TLQP-21 activity reside at the C terminus. In fact,
alanine-scanning mutagenesis and two bioassays including
fundus strip contraction and lipolysis in 3T3L1 cells showed
that the C-terminal sequence (-PPAR21) is central to TLQP-21
biological activity (Table 1). A similar situation is found for the
C3a peptide, the first ligand ever identified for the C3aR1 (Nette-
sheim et al., 1988). In the absence of the receptor, the C3a
peptide is organized in helical segments interrupted by short
flexible loops that become less defined at residue 66 (Klos
et al., 2013), while they adopt a significantly more ordered helical
Table 1. Contractile Activity on Rat Stomach Fundus Exerted by
TLQP-21 Mutants
Peptide
Activity % of TLQP-21
(Average ± SEM)
TLQPPASSRRRHFHHALPPAR 100
TLQPPASSRRR inactive
HFHHALPPAR 2.6 ± 4*
TLQPPASSRRRAFHHALPPAR 95 ± 4
TLQPPASSRRRHAHHALPPAR 88 ± 9
TLQPPASSRRRHFAHALPPAR 91 ± 5
TLQPPASSRRRHFHAALPPAR 84 ± 10
TLQPPASSRRRHFHHALAPAR (P18A) 65 ± 7**
TLQPPASSRRRHFHHALPAAR (P19A) 19 ± 4*
TLQPPASSRRRHFHHALPPAA (R21A) inactive
TLQPPASSRRRHFHHALPPAR-NH2 inactive
TLQPPSALRRRHYHHALPPSR (human) 20 ± 9***
Mutation underlined. *p < 0.001; **p > 0.5; ***p < 0.01.
Structure
Structural and Functional Analysis of TLQP-21 Peptideconformation in the crystal lattice (Nettesheim et al., 1988). As
with TLQP-21, the C3a peptide’s hot spots are located at the
C terminus, and R77 plays a critical function (Ames et al.,
2001; Hugli and Erickson 1977; Nettesheim et al., 1988). By
deleting the C-terminal R77 of C3a, it is possible to ablate the
peptide’s function at C3aR1 completely, although the deletion0
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Structure 22, 1744–17mutant is still able to form an ordered helix (Nettesheim et al.,
1988). A very similar result was obtained with TLQP-21. The
R21A mutant of TLQP-21 is inactive while still undergoing an a
helix conformational change. A full understanding of the similar-
ities in the mechanism of action of TLQP-21 and C3a is currently
lacking. In CHO and HeK239 cells transfected with C3aR1,
TLQP-21 binds the receptor with 100-fold lower affinity than
C3a (Hannedouche et al., 2013), whereas both these ligands
induce a similar contraction of gastric fundus strips (present
data) and insulin release (Stephens et al., 2012; Lo et al.,
2014). Conversely, mouse TLQP-21 enhances isoproterenol-
induced lipolysis in mouse adipocytes (Possenti et al., 2012)
and murine 3T3L1 (present study), whereas in an heterologous
system, Lim et al. (2013) showed that human serum C3a exerts
the opposite effect in murine 3T3L1 cells. Finally, using mouse
genetic models, C3aR1 knockout mice are transiently resistant
to diet-induced obesity and are protected from insulin resistance
and liver steatosis (Mamane et al., 2009), similar to VGF
knockout mice (Hahm et al., 1999, 2002). In conclusion, although
the mechanism of binding to the C3aR1 receptor may appear
similar for both TLQP-21 and C3a, differences in their primary
sequences might account for the nonfully overlapping biological
actions.
Another important finding of our investigation relates to
the different function between human and rodent TLQP-21
sequences. A recent study reported that the human TLQP-21
sequence is 5-fold less potent toward the rodent C3aR1 than**
**
NS
*
+ + +
- + -
- - +
5055
1
l shift (ppm)
Figure 5. TLQP-21, but Not R21A, Mutant
Enhances Lipolysis in 3T3L1
(A) TLQP-21 potentiates lipolysis induced by the
b-adrenergic receptor agonist isoproterenol (ISO)
(F(5,65) = 62.1, p < 0.0001).
(B) Unlike TLQP-21, the R21Amutant peptide does
not potentiate isoproterenol-induced lipolysis in
3T3L1 adipocytes (F(5,65) = 33.4, p < 0.00001).
(C) Refocused INEPT spectra of R21A mutant,
labeled with 13C and 15N at A16-L17-P18 with
resonance assignments indicated. Experiments
were performed in buffer (left) or in the presence of
3T3L1 cells (right). *p < 0.05, **p < 0.001.
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Here, we tested the potency of these two peptides toward the
human C3aR1 receptor and found that both human and
mouse TLQP-21 sequences target the human receptor with
different potency. Specifically, we found an EC50 for the
mouse TLQP-21 approximately three times lower than that
for the C3a peptide, whereas the corresponding EC50 for the
human TLQP-21 is approximately 22 times lower (Figure 1C).
The rodent (rat and mouse) and primate (human, chimpanzee,
and macaque) TLQP-21 sequences differ by four amino acids
(Bartolomucci et al., 2011). However, Ala20 at the C terminus
of the rodent peptide is substituted by Ser20 in the human
sequence (Table 1), resulting in a mutation leading to a pep-
tide with lower potency toward the primate and the rodent
C3aR1. In support, mutations at the C terminus of C3a reduce
the affinity toward the human receptor (Klos et al., 2013).
Interestingly, casoxin C (Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-
Arg) and Oryzatensin (Gly-Tyr-Pro-Met-Tyr-Pro-Leu-Pro-Arg)
are short bioactive peptides with sequence analogy with the
human complement C3a70–77 and substitution of Ala76 in
C3a with either Ser or Pro, respectively (Takahashi et al.,
1996, 1997). The biological activity of casoxin C and oryza-
tensin in the ileum-contraction assay is similar to that of
C3a70–77 but with lower potency (Takahashi et al., 1996,
1997). Overall, these data suggests that, unlike the mutation
of the Arg77/Arg21 that abrogates activity at the C3aR1 (see
above), mutating the Ala76 in C3a and Ala20 in TLQP-21 could
reduce their biological activity.
Based on our finding that TLQP-21 enhances lipolysis in adi-
pocytes (Figure 5; Possenti et al., 2012), the lower potency of
the human TLQP-21 peptide might reduce the lipolytic potential
of humans and may constitute one of the factors explaining hu-
man vulnerability to obesity. Conversely, the rodent peptide
could represent a gain-of-function mutation with respect to the
basal TLQP-21 activity toward the C3aR1 receptor and suggests
possible point mutations for augmenting or reducing TLQP-21
potency in humans. The latter will have implications in the design
of synthetic ligands that mimic a-helical conformations to target
C3aR1 and activate lipolysis to treat obesity and obesity-related
disorders. Synthetic molecules designed to target GPCRs have
already been developed into potent agonists and antagonists
by engineering lactam-bridges promoting a-helical structures
(Neelamkavil et al., 2005; Ammoun et al., 2003; Grace et al.,
2007; Murage et al., 2008; Pellecchia et al., 2008). The mouse
TLQP-21 sequence represents a molecular template for
designing new analogs of this peptide that can serve as agonists
or antagonists for C3aR1 having important implications for
obesity (Possenti et al., 2012), diabetes (Stephens et al., 2012),
hypertension (Fargali et al., 2014), pain (Fairbanks et al., 2014),
and potentially immune functions.
In summary, our results show a folding-upon-binding mecha-
nism for TLQP-21 that activates the cognate C3aR1 receptor,
leading to enhanced lipolysis in adipocytes. Using a combination
of spectroscopic and biological assays, we identified the hot
spots for TLQP-21 function as residing at the C-terminal
sequence of the peptide. C-terminal amidation or mutation of
the basic arginine 21 residue obliterates peptide function, sug-
gesting that both positive and negative electrostatic interactions
at the C terminus are necessary for biological activity.1750 Structure 22, 1744–1753, December 2, 2014 ª2014 Elsevier LtdThis study represents a major step toward understanding
the molecular mechanism for activation of TLQP-21 and
paves the way for designing new agonists/antagonists to modu-
late the function of the C3aR1 receptor (Reid et al., 2013).EXPERIMENTAL PROCEDURES
Peptide Synthesis and NMR Spectroscopy
General
All solvents used were high-performance liquid chromatography (HPLC)
grade. DIEA and TFA (peptide synthesis grade) were purchased from Fisher.
Fmoc-protected amino acids, HBTU and HOBt, were purchased from
AnaSpec. Preloaded Fmoc-AA-PEG-PS resins were purchased from Applied
Biosystems. N-Fmoc isotopically labeled amino acids were purchased from
Cambridge Isotope Laboratories. All other reagents were obtained from
Sigma-Aldrich.
Synthesis of TLQP21
Starting with Fmoc-ARGPEG-PS resin (initial loading 0.18 mmol/g), the
21-residue peptide TLQP21 was synthesized using Fmoc solid-phase synthe-
sis on a CEM microwave peptide synthesizer. Side chain protecting groups
were 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, triphe-
nylmethyl (Trt) for Gln and His, and tert-butyl ethers (tBu) for Ser and Thr. Fmoc
removal was achieved using a solution of 20% piperidine in N,N-dimethylfor-
mamide for 5 min. HBTU/HOBt/DIEA couplings required 7 min preactivation
time following reaction times of 60 min. Upon reaction completion, the pep-
tide-resin was deprotected and cleaved from the resin in batches of 200 mg
with 2 ml of reagent B: 85% trifluoroacetic acid (TFA), 5% phenol, 5% water,
5% triisopropylsilane for 4 hr at 25C under mechanical stirring. The cleavage
mixture was then filtered and the resin was washed with 2 ml reagent B. The
cleaved peptide fractions were pooled together and precipitated by addition
of 200 ml of cold diethyl ether and incubated for 24 hr at 4C. The precipitated
peptide was collected by centrifugation and washed three times with 200ml of
cold diethyl ether. The crude peptide pellet was dried under N2 gas flow and
dissolved in 50 ml of HPLC grade water. The crude peptide was filtered using
a 0.2 mm polycarbonate filter and purified by reverse-phase HPLC on a C18
preparative column (Vydac, 218TP15 C18; 15 mm particles, 22 3 250 mm).
The crude peptide solution was pre-equilibrated with 90% HPLC buffer A
(99.9% water, 0.1% TFA) with a flow rate of 10 ml/min. Peptide purification
protocol consisted of (1) linear gradient from 10% to 20% of buffer B (acetoni-
trile and 0.1% TFA) in 30 min, and (2) subsequent isocratic elution. Fractions
containing peptides were determined by analytical HPLC and pooled together
before lyophilization. The molecular weight of the purified peptide was deter-
mined using electrospray ionization mass spectroscopy (Agilent MSD SL Ion
Trap). To remove TFA ions from the peptide, a simple exchange method
was followed. Briefly, ion exchange resin (AG1-X8, Biorad) was prepared by
washing with 10 vol of acetic acid (1.6 M), followed by 10 vol of acetic acid
(0.16 M) and 5 vol of water. Purified peptide was dissolved in water at a con-
centration of approximately 4 mg/ml and loaded onto the equilibrated resin.
After 1 hour of incubation with shaking, the peptide was eluted from the resin
by gravity and the resin was washed with water. Pooled peptide was aliquoted
and the volume accurately measured. Samples from several aliquots were
taken and submitted for amino acid analysis. Amino acid analysis was
performed by the Protein Chemistry Laboratory (Texas A&M University). Ion-
exchanged peptides were lyophilized and stored at 20C until use.
NMR Spectroscopy
For solution NMR experiments (Veglia et al., 2012), the TLQP-21 peptide
powder was dissolved in 120 mM NaCl, 20 mM NaHPO4, pH 7.0, 5% D2O,
and transferred into a Shigemi tube. Heteronuclear single quantum and multi-
ple quantum correlation experiments were run to verify the labeling pattern in
the isotopically labeled peptides. MAS samples were prepared by dissolving
0.5 to 1 mg of TLQP-21 in 20 ml of 20 mM phosphate buffer, 120 mM NaCl
at pH 7.0. The suspension was vortexed and briefly sonicated. The mixture
was transferred to a 3.2 mm thin wall rotor MAS rotor. 3T3L1, N38, or spleno-
cytes were centrifuged in 1.5 ml microfuge tubes for 2 min at 13,300 rpm.
Twenty microliters of wet cell pellet was pipetted into a clean 0.5 ml microfuge
tube and (where applicable) incubated with the selective C3aR1 antagonist SB
290157 for 3 hr at 4C. The cell pellet was added to 1.0 mg of lyophilizedAll rights reserved
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mixture was transferred to a 3.2 mm thin wall rotor MAS rotor. All of the
NMR experiments were performed on a VNMRS spectrometer operating at
a proton frequency of 600 MHz. One-dimensional 13C spectra were acquired
using a cross-polarization sequence with 1ms contact time and spectral width
of 100 kHz. The sample was spun at 8 kHz and the temperature was main-
tained at 37C. Chemical shifts were assigned using rINEPT and total through
bond correlation spectroscopy experiments acquired using a BioMAS probe.
Pulse widths were 5.5 ms (13C, 15N), 2.5 ms (1H) with 100 kHz (direct 13C dimen-
sion), and 3.33 kHz (indirect 1H dimension) spectral widths. Typically, 128
scans with 30 increments in the indirect dimension were acquired. The data
were processed using NMRPipe and analyzed with Sparky software.
Secondary Structure Prediction
To analyze the secondary structure propensity of TLQP-21, two programs
were used: PredictProtein and JUFO. PredictProtein (www.predictprotein.
org) is an automatic Internet service that includes software for the prediction
of protein structure and function. The JUFO (http://www.meilerlab.org/index.
php/servers/show?s_id=5) server provides a simultaneous prediction of sec-
ondary structure and transmembrane spans from the protein sequence. It
uses an artificial neural network trained on databases of membrane proteins
and soluble proteins.
Splenocyte Isolation
BALB/cJ and C3aR1 knockout mice were euthanized with CO2 and spleens
were harvested. Spleens were placed in complete media and filtered to yield
a single-cell suspension. Splenocytes were seeded at 1 3 106 cells/ml and
stored in an incubator (37C, 5% CO2) for 4 hr until NMR sample preparation.
Full details appear in the Supplemental Experimental Procedures.
Gastric Contraction Assay
Wistar female rats (250–350 g; Charles River) were euthanized by inhalation of
75% CO2 in air. The stomach was removed and washed in fresh Tyrode’s so-
lution as previously described (Severini et al., 2009), and the assay performed
as previously described and detailed in the Supplemental Experimental Proce-
dures. Data were analyzed with unpaired t tests. All animal experiments were
approved by the Ethics Committee of the Italian Ministry of Health.
Receptor Crosslinking Experiment
Crosslink peptide with N-terminal biotin and benzoylphenylalanine (Bpa)
substitution of H12 was purchased from AAPPTec, purified by HPLC as the
acetate salt, and verified by mass spectrometry.
Membrane Preparation
Confluent CHO and 3T3L1 cells were washed twice with cold PBS before col-
lecting the cells by scraping into cold homogenization buffer (20 mM HEPES,
1 mM EDTA, 255 mM sucrose, pH 7.6). Cells were briefly sonicated to lyse,
then centrifuged 20 min at 10,000 3 g at 4C. The precipitated membranes
(P1) were resuspended in resuspension buffer (20 mM HEPES, 1 mM EDTA,
pH 7.6). The supernatants were transferred to fresh tubes and centrifuged
60 min at 41,000 3 g at 4C. These precipitated membranes (P2) were also
resuspended in resuspension buffer. Both membrane protein concentrations
were determined by BCA assay (Pierce).
Crosslinking
3T3L1 and CHO membranes were diluted with PBS to 0.5 mg/ml protein. One
milliliter of dilutedmembraneswas aliquoted into a 96-well plate. An equivalent
volume of TLQP-21 crosslink peptide was added to the diluted membranes
and incubated for 10 min at room temperature. The 96-well plate was then
placed on ice and transferred to the cold room for crosslinking. Crosslinking
was achieved by a UV lamp (8 W, 365 nm) for 30 min. Aliquots were collected
from the 96-well plate and combined. In some cases (P2ppt), proteins were
precipitated through addition of trichloroacetic acid to achieve a 6% solution.
After 30 min incubation on ice, the samples were centrifuged to isolate the
protein pellets. The protein pellets were washed twice with cold acetone and
then resuspended in RIPA buffer (25 mM Tris base, 150 mM NaCl, pH 8.0,
1% deoxycholic acid, 1% Triton X-100).
Western Blotting
Aliquots of either the crosslinked P1 or P2 membrane solution or the solubi-
lized precipitated membrane solution (P2ppt) were loaded onto 4%–12%
bis-TRIS gels and separated with MOPS buffer (Invitrogen) before transfer toStructure 22, 1744–17nitrocellulose membranes. After blocking for 1 hr in 5% milk in TBS-T, the
membranes were washed four times for 10 min with TBS-T and blotted with
guinea pig anti-TLQP-21 antibody (Possenti et al., 2012; 1:10,000 5% BSA)
for 72 hr at 4C, and then 90 min in anti-guinea pig IRDye 680RD (Li-Cor,
926-68077). The membranes were then scanned by Li-Cor Odyssey.
GPCR b-arrestin Recruitment Assay: G Protein Independent
The assay was performed as previously reported (Lin et al., 2013). Additional
details appear in the Supplemental Experimental Procedures.
Lipolysis and Western Blotting in 3T3L1 Adipocytes
The 3T3-L1 cell line was obtained from the Minnesota Obesity Center.
During proliferation, these cells show a similar morphology to fibroblasts.
Once 3T3-L1 fibroblast cells reach confluence, they are exposed to an
adipogenic cocktail including fetal bovine serum, dexamethasone, methyli-
sobutylxanthine, and insulin (Possenti et al., 2012; Green and Kehinde,
1975). Induction of differentiation triggers profound phenotypical changes,
from elongated to spherical, filled with lipid droplets displaying many
morphological characteristics of adipocytes, as well as biochemical
changes, expression of specific adipogenic transcription factors, and genes.
At the fully differentiated stage, these cells can be used to study adipocyte
metabolism and function.
Lipolysis Assay in 3T3 L1
At day 8 of differentiation, 3T3-L1 adipocytes differentiated on six-well plates
were first starved for 3 hr in KRHwith 1%BSA, then incubated with TLQP-21 in
the presence and absence of specific agonists/antagonists, as clarified above,
suspended in KRH with 4% BSA. Following 3 hr of incubation at 37C and 5%
CO2, the media was collected and incubated at 60
C for 20 min to inactivate
any residual enzymatic reaction activity. The cells were gathered for protein
concentration or trypsinized for cell diameter and viability measurements. At
least three independent experimental replicates were performed for each
treatment.
Western Blotting
Cells were from ATCC and differentiated as described above. Equivalent
amounts of cell extracts (approximately 5 3 105 cells) were mixed with
SDS- reducing sample buffer according to Invitrogen Nu PAGE (Invitrogen).
Incubation with primary antibodies was performed overnight at 4C with
anti-Phospho-AMPK(Thr172) (Cell Signaling Technology). Anti-tubulin was a
monoclonal antibody from Sigma. Secondary antibodies were donkey anti-
rabbit or anti-mouse peroxidase-coupled (Amersham). A semiquantitative
analysis of western blots densitometry scan was performed using Scan Anal-
ysis software ImageJ. Data were analyzed with ANOVA followed by Tukey’s
post hoc tests.
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